Clinical Trials Logo

Type1 Diabetes clinical trials

View clinical trials related to Type1 Diabetes.

Filter by:

NCT ID: NCT04233034 Completed - Type1 Diabetes Clinical Trials

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

CLVer
Start date: July 9, 2020
Phase: Phase 3
Study type: Interventional

Randomized trial of youth aged 7-<18 years with newly diagnosed stage 3 type 1 diabetes (T1D) to assess the effect of both (1) near-normalization of glucose concentrations achieved through use of a hybrid closed loop (HCL) system and (2) verapamil on preservation of β-cell function 12 months after diagnosis. Participants with body weight ≥30 kg (Cohort A) will be randomly assigned in a factorial design to (1) HCL plus intensive diabetes management or usual care with no HCL and (2) verapamil or placebo. Participants with body weight <30 kg (Cohort B) will be randomly assigned 2:1 in a parallel group design to HCL plus intensive diabetes management or to usual care with no HCL.

NCT ID: NCT04002557 Completed - Type1 Diabetes Clinical Trials

Optimising Consultation Summaries to Promote Good Health

ONSET
Start date: May 31, 2019
Phase:
Study type: Observational

Patient participation in decision making about their care promotes patient satisfaction and confidence. Further more, allowing patients to see letters written about them enables trust, encourages patients to be involved in decision making process and allow patient understanding. Little is known about how young people value these letters in the same way. Only one brief questionnaire study focused on adolescent views and found that young people wished to receive consultation summaries. This research aims explore the views of adolescent patients related to consultation summaries that they receive following a doctor's appointment. The investigator will use patients attending a specialist diabetes clinic as our cohort and conduct a qualitative study using focus groups.

NCT ID: NCT03782636 Active, not recruiting - Type1 Diabetes Clinical Trials

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

ITAD
Start date: January 28, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes. One group will receive aldesleukin and the other a placebo.

NCT ID: NCT03236558 Withdrawn - Type1 Diabetes Clinical Trials

The Role of the Thymus in Type I Diabetes.

TregDiab
Start date: March 2018
Phase: N/A
Study type: Interventional

Regulatory T lymphocytes play a major role in the protection from autoimmune pathology. Defects in immunosuppression mediated by these cells is therefore suspected to contribute to these diseases. This issue has very little been studied in humans.Regulatory T cells emigrated from the thymus will be isolated from the blood of patients and healthy controls. The repertoire of antigen-receptors will be analysed by high throughput sequencing and its diversity estimated using appropriate statistical models borrowed from ecology.

NCT ID: NCT03179280 Completed - Type1 Diabetes Clinical Trials

Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia

Start date: March 2011
Phase: N/A
Study type: Interventional

A study was conducted in adolescents with type 1 diabetes (T1D) examining the effect of different bolus types on 6-h postprandial glucose levels after the consumption of 3 standard meals with varying composition. Participants were asked to consume 10 different combinations of meal and bolus type.

NCT ID: NCT01838083 Completed - Type1 Diabetes Clinical Trials

Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus

Start date: April 2013
Phase: Phase 1
Study type: Interventional

Primary Objective: To demonstrate equivalence in exposure to insulin glargine given as test formulation T and reference formulation R in steady state conditions after 6 once-daily subcutaneous (SC) doses Secondary Objective: - To assess relative Pharmacodynamic activity of the insulin glargine test formulation T to the insulin glargine reference formulation R in steady state conditions after 6 once-daily SC doses - To assess the safety and tolerability of the test and reference formulations of two new insulin glargine formulations

NCT ID: NCT01357603 Completed - Type1 Diabetes Clinical Trials

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

Start date: June 2011
Phase: Phase 1
Study type: Interventional

The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.